紫杉醇脂质体联合顺铂治疗复发卵巢癌的临床观察

目的观察紫杉醇脂质体联合顺铂治疗复发卵巢癌的效果。方法 将82例复发卵巢癌病人分成2组, 试验组(40例)和对照组(42例), 试验组每个疗程给予紫杉醇脂质体135mg/m², 在治疗的d 1, 8静脉滴注(静滴);顺铂100mg/m², 分d 1-5静滴;对照组氟脲嘧啶1500mg和顺铂100mg/m², 按常规剂量给予。观察两组卵巢癌上皮抗原(CA125)值、病灶缩小情况、生存率、不同病理类型对其敏感度以及不良反应的差异。结果 试验组CA125下降率27%, 病灶缩小率32%, 1年生存率72%, 对照组分别为10%、10%、35%, 差异有显著意义(P＜0.05)。透明细胞癌较浆液性癌对紫杉醇脂质体敏感。试验组的不良反应主要是腹泻、呕吐、中性粒细胞减少和神经毒性。结论 紫杉醇脂质体联合顺铂是一种治疗复发卵巢癌有效方案。

Clinical observation of paclitaxel liposome and cisplatin in the treatment of recurrent ovarian cancer

Objective To observe the results of paclitaxel liposome and cisplatin in the treatment of recurrent ovarian cancer. Methods 82 cases of recurrent ovarian cancer were divided into 2 groups, experimental group（40 cases）and control group （42 cases）, each experimental group was given paclitaxel liposome treatment 135 mg/m^2, 1,8 - day intravenous infusion （intravenous） ;cisplatin 100 mg, at the first intravenous infusion of 1 - 5 days ; control group, 1 500 mg of fluorouracil and cisplatin 100 mg, given in accordance with conventional doses. Epithelial ovarian cancer antigen（ CA125 ） value, narrow focus, the survival rate, the sensitivity of different pathological types, as well as adverse reactions were observed. Results CA125 decline in the rate of 27 percent, the rate of lesion reducing was 32% , 1 -year survival rate of 72%, in the control group were 10% , 10% and 35% respectively,the difference was significant（P 〈0.05 ）. Clear cell carcinoma was more sensitive to paclitaxel liposome than that of serous carcinoma. The main adverse reactions of the experimental group were diarrhea, vomiting, neutropenia,intestinal obstruction and neurotoxicity. Conclusion Paclitaxel lipesomes and cisplatin could be an effective treatment program for recurrent ovarian cancer.